Atrium Therapeutics, Inc. Common Stock Working Capital to Net Assets Ratio
Atrium Therapeutics, Inc. Common Stock working capital to net assets ratio. Atrium Therapeutics, Inc. Common Stock (RNA) has a Working Capital to Net Assets ratio of 111.5% as of December 2025. Working capital of $231.04 Million (current assets of $272.85 Million minus current liabilities of $41.80 Million) is measured against net assets of $207.29 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Atrium Therapeutics, Inc. Common Stock tangible book value ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Atrium Therapeutics, Inc. Common Stock (2018–2025)
Working capital to net assets ratio of Atrium Therapeutics, Inc. Common Stock from 2018 to 2025. This chart shows how Atrium Therapeutics, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 8 annual periods from 2018 to 2025. As of December 2025, the ratio stands at 111.5%, reflecting working capital of $231.04 Million against net assets of $207.29 Million USD. See Atrium Therapeutics, Inc. Common Stock (RNA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Atrium Therapeutics, Inc. Common Stock Working Capital to Net Assets Ratio by Year (2018–2025)
Atrium Therapeutics, Inc. Common Stock working capital to net assets ratio by year from 2018 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Atrium Therapeutics, Inc. Common Stock from 2018 to 2025, covering 8 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Atrium Therapeutics, Inc. Common Stock total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 111.5% | $231.04 Million | $207.29 Million | $272.85 Million | $41.80 Million | ▲ +10.1 pp |
| 2024 | 101.4% | $1.44 Billion | $1.42 Billion | $1.54 Billion | $98.02 Million | ▼ -4.6 pp |
| 2023 | 106.0% | $530.63 Million | $500.76 Million | $611.31 Million | $80.68 Million | ▲ +7.2 pp |
| 2022 | 98.8% | $571.03 Million | $578.08 Million | $622.94 Million | $51.91 Million | ▼ -1.2 pp |
| 2021 | 100.0% | $381.48 Million | $381.43 Million | $411.14 Million | $29.66 Million | ▼ -3.5 pp |
| 2020 | 103.5% | $317.09 Million | $306.22 Million | $331.68 Million | $14.59 Million | ▲ +234.3 pp |
| 2019 | -130.7% | $85.44 Million | $-65.36 Million | $95.68 Million | $10.24 Million | ▼ -134.1 pp |
| 2018 | 3.3% | $-1.37 Million | $-41.13 Million | $3.24 Million | $4.62 Million | — |